نتائج البحث - "Minh H Dinh"

المصدر: Coleman, R L, Fleming, G F, Brady, M F, Swisher, E M, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K N, Efrat Ben-Baruch, N, Werner, T L, Cloven, N G, Oaknin, A, DiSilvestro, P A, Morgan, M A, Nam, J-H, Leath, C A, Nicum, S, Hagemann, A R, Littell, R D, Cella, D, Baron-Hay, S, Garcia-Donas, J, Mizuno, M, Bell-McGuinn, K, Sullivan, D M, Bach, B A, Bhattacharya, S, Ratajczak, C K, Ansell, P J, Dinh, M H, Aghajanian, C & Bookman, M A 2019, ' Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer ', The New England Journal of Medicine, vol. 381, no. 25, pp. 2403-2415 . https://doi.org/10.1056/NEJMoa1909707

مصطلحات موضوعية: Oncology, Benzimidazoles/adverse effects, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Administration, Oral, 030204 cardiovascular system & hematology, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Ovarian Neoplasms, Aged, 80 and over, Cystadenocarcinoma, Serous/drug therapy, Ovarian Neoplasms/drug therapy, General Medicine, Middle Aged, Combined Modality Therapy, Progression-Free Survival, Intention to Treat Analysis, Female, Adult, medicine.medical_specialty, Paclitaxel, Veliparib, Poly(ADP-ribose) Polymerase Inhibitors, Article, Maintenance Chemotherapy, 03 medical and health sciences, Double-Blind Method, Paclitaxel/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Aged, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, medicine.disease, Cystadenocarcinoma, Serous, Clinical trial, Adenosine diphosphate, chemistry, Mutation, Quality of Life, Benzimidazoles, Ovarian cancer, business, Poly(ADP-ribose) Polymerase Inhibitors/adverse effects

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca7b04b7c61e036ac9e46850f4d7173
https://doi.org/10.1056/nejmoa1909707

Find this article in full text from ProQuest

6

Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study

المؤلفون: Elizabeth M. Swisher, Carol Aghajanian, David M. O'Malley, Gini F. Fleming, Scott H. Kaufmann, Douglas A. Levine, Michael J. Birrer, Kathleen N. Moore, Nick M. Spirtos, Mark S. Shahin, Thomas J. Reid, Michael Friedlander, Karina Dahl Steffensen, Aikou Okamoto, Vasudha Sehgal, Peter J. Ansell, Minh H. Dinh, Michael A. Bookman, Robert L. Coleman

المصدر: Swisher, E M, Aghajanian, C, O'Malley, D M, Fleming, G F, Kaufmann, S H, Levine, D A, Birrer, M J, Moore, K N, Spirtos, N M, Shahin, M S, Reid, T J, Friedlander, M, Steffensen, K D, Okamoto, A, Sehgal, V, Ansell, P J, Dinh, M H, Bookman, M A & Coleman, R L 2022, ' Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study ', Gynecologic Oncology, vol. 164, no. 2, pp. 245-253 . https://doi.org/10.1016/j.ygyno.2021.12.003

مصطلحات موضوعية: Adult, Paclitaxel, Genes, BRCA2, Genes, BRCA1, Loss of Heterozygosity, Allelic Imbalance, Carcinoma, Ovarian Epithelial, Poly(ADP-ribose) Polymerase Inhibitors, Genomic Instability, Carboplatin, Maintenance Chemotherapy, Young Adult, BRCA1/2, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Ovarian Neoplasms, Veliparib, Recombinational DNA Repair, Obstetrics and Gynecology, Cytoreduction Surgical Procedures, Induction Chemotherapy, General Medicine, Middle Aged, Progression-Free Survival, Oncology, CA-125 Antigen, Hereditary Breast and Ovarian Cancer Syndrome, Benzimidazoles, Female, Homologous recombination deficiency

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4581455fdf487d12d2578e534388cdd5
https://doi.org/10.1097/01.ogx.0000827620.82650.68

7

Characterization of patients with BRCA mutated ovarian cancer who are eligible versus not eligible for PARP inhibitor maintenance therapy: exploratory analysis of the VELIA study

المؤلفون: Peter Ansell, Karina Dahl Steffensen, Kathleen N. Moore, Aikou Okamoto, Christine K. Ratajczak, Danielle Sullivan, Robert L. Coleman, Minh H. Dinh, Brenden Chen, Scott H. Kaufmann, Bruce A. Bach, Elizabeth M. Swisher, Michael A. Bookman

المصدر: Swisher, E, Kaufmann, S, Okamoto, A, Steffensen, K, Bookman, M, Moore, K, Sullivan, D, Bach, B, Ratajczak, C, Chen, B, Dinh, M, Ansell, P & Coleman, R 2021, ' Characterization of patients with BRCA mutated ovarian cancer who are eligible versus not eligible for PARP inhibitor maintenance therapy: exploratory analysis of the VELIA study ', Gynecologic Oncology, vol. 162, no. Suppl. 1, pp. S106-S107 . https://doi.org/10.1016/S0090-8258(21)00846-5

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d5f71e65265838f2a5eddbbaef9d45
https://portal.findresearcher.sdu.dk/da/publications/05d497fe-54cd-4876-920b-a4892131e8dd

8

16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer

المؤلفون: David Cella, N. Khandelwal, K. Benjamin, Danielle Sullivan, Robert L. Coleman, M. A. Bookman, Minh H. Dinh, Rajesh Kamalakar, Angeles Alvarez Secord

المصدر: Oral Plenary.

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Veliparib, business.industry, Nausea, Placebo, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Toxicity, medicine, Vomiting, Progression-free survival, medicine.symptom, Adverse effect, business, Ovarian cancer

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7dafafb2d2ffbaf512039accdfd69052
https://doi.org/10.1136/ijgc-2020-igcs.16

9

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)

المصدر: Coleman, R L, Fleming, G F, Brady, M F, Swisher, E, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K, Ben-Baruch, N, Werner, T L, Oaknin, A, Nam, J-H, Leath III, C A, Nicum, S, Cella, D, Sullivan, D M, Ansell, P J, Dinh, M, Aghajanian, C & Bookman, M A 2019, ' VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) ', Annals of Oncology, vol. 30, no. Suppl. 5, LBA3, pp. 895-896 . https://doi.org/10.1093/annonc/mdz394.054

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Veliparib, business.industry, Serous cystadenocarcinoma, Hematology, Debulking, medicine.disease, Chemotherapy regimen, Carboplatin, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, Peritoneum, Internal medicine, medicine, Progression-free survival, business, Fallopian tube

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ba78554549a175a0c325f3783e0c9a
https://portal.findresearcher.sdu.dk/da/publications/ac0d1969-1c86-4c6d-944a-80a0f8a178b0

10

Exploring the relationship between homologous recombination score and progression-free survival in BRCA wildtype ovarian carcinoma: Analysis of veliparib plus carboplatin/paclitaxel in the velia study

المؤلفون: Kirsten Timms, Gini F. Fleming, Robert L. Coleman, Michael A. Bookman, Danielle Sullivan, Scott H. Kaufmann, Michael J. Birrer, Bruce A. Bach, Douglas A. Levine, Minh H. Dinh, Vasudha Sehgal, Kathleen N. Moore, Peter Ansell, Carol Aghajanian, Elizabeth M. Swisher, Brenden Chen

المصدر: Gynecologic Oncology. 159:51

مصطلحات موضوعية: Veliparib, business.industry, Wild type, Obstetrics and Gynecology, Carboplatin/paclitaxel, chemistry.chemical_compound, Oncology, chemistry, Ovarian carcinoma, Cancer research, Medicine, Progression-free survival, Homologous recombination, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3a523664f6d71be1137b1af341326287
https://doi.org/10.1016/j.ygyno.2020.06.107

View record from ScienceDirect

Full Text via ClinicalKey

تنقيح النتائج